________________________________________________________________________________________________________________________________

xxxStem Cell Research Now and in the Future

November 2009. “Stem cells provide novel opportunities that didn't previously exist” says Dr Patrick Vallance, today President Pharmaceuticals, R&D of GlaxoSmithKline in the exclusive interview with B2Bioworld. He describes his company’s approach. What is the role of cancer stem cells? What about novel drugs like lapatinib or trastuzumab? Which collaborations are desirable? The interview includes stem cell issues yet unattended by pharma.

 

 

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 3 pages
- Includes independent ranking of partnering capabilities of GlaxoSmithKline

Full Company License enquire here

Back to section

Related Editorial Articles

Patient-centered Precision Care
Michael Christman, President of the Coriell Institute for Medical Research at Camden, New Jersey (US), talks about some tricky issues of turning research on genotyping into healthcare routines

Pfizer Regenerative Medicine (Neusentis): It really started last year…
Ruth McKernan, global CSO of Pfizer’s Regenerative Medicine Unit (today Neusentis) addresses basic and practical issues in pharmaceutical research on stem cells

Sanofi: Triggering Regenerative Functions with Transplanted Cells and Small Molecules
Kurt Stoeckli, Global Head of Biological Sciences / Discovery Sanofi Aventis and Scientific Director

The Myriad Way
Peter D Meldrum, CEO of the genetics company about battles on patents, cancer chips, and competitors in commercial academia

Leroy Hood: Thinking Further about Stem Cells

Novartis: Preparing for Another Level of Innovation
Mark Fishman, President of the Novartis Institutes for BioMedical Research and Member of the Executive Committee of Novartis, comments his company’s strategy in the stem cells field including technology acquisitions in the field

Patenting Stem Cells – Behind the Front Stages
The patentability of stem cells is of continuing debate. The article outlines the legal approach to stem cells as it informs solving juridical problems

Stem Cells – Failings and Deliveries
Hugh Ilyine, former longtime COO of Stem Cell Sciences looks at clinical trials, reimbursement prospects, and interest of venture capital

Novo Nordisk: Doing our business a little bit differently than the others in industry
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk on stem cell approaches to diabetes

Drug Testing with Embryonic Stem Cells
- Towards standards for assays

Metrics for Disease, Health, and Wellness
Personalized medicine? A systems look at human genetic diagnostics and the road ahead for next-generation sequencing by Leroy Hood, Institute for Systems Biology at Seattle

L'Oréal Makes Progress in Stem Cell Research